Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Trends and Insights

Increasing Diagnosis of Persistent and Chronic ITP

Clinical underdiagnosis historically limited the apparent patient base for the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market. A French registry of 541 adults found that 46% were at least 65 years old at presentation, and 47% of that older group were at least 80 years old.^{[1]Source: G. Moulis et al., “Immune Thrombocytopenia in the Elderly: Immunosenescent and Clinical Diversity,” British Journal of Haematology, onlinelibrary.wiley.com.}China’s 2025 adult ITP guideline revised diagnostic and treatment guidance and reduced uncertainty around initial treatment eligibility. PMC.NCBI.NLM.NIH.GOV More consistent identification of patients can increase the number entering hematology care. Persistent and chronic disease creates continuing treatment needs after an initial diagnosis. Better hematology capacity in South Korea, India, and Australia is also bringing previously unrecognized cases into treatment pathways.

Shift Toward Targeted Steroid-Sparing Therapies

Corticosteroids remain a common first treatment, but durable remission after withdrawal occurred in only 20% to 40% of patients in the cited clinical evidence. Extended steroid use is also associated with hyperglycemia, osteoporosis, and cardiovascular events. This clinical gap supports the use of thrombopoietin receptor agonists and creates room for newer targeted therapies. In the LUNA 3 study, rilzabrutinib produced a durable platelet response in 23% of treated patients, compared with 0% for placebo. At 12 weeks, 64% of treated patients achieved a platelet response, and quality-of-life scores improved by 10.6 points compared with 2.3 points for placebo. These findings support earlier consideration of steroid-sparing treatment in appropriate patients.

FcRn, BTK, SYK, and B-Cell Pathway Innovation

The Idiopathic thrombocytopenic purpura (ITP) therapeutics market has several drug classes in clinical development or early commercialization. FcRn antagonists aim to reduce pathogenic immunoglobulin G, while BTK and SYK inhibitors target different parts of the immune pathway involved in platelet destruction. In a Phase 3 study, intravenous efgartigimod achieved a sustained platelet response in 22% of patients compared with 5% for placebo. Rilzabrutinib became the first BTK inhibitor approved in the United States for adults with persistent or chronic ITP who had an insufficient response to prior therapy. Agios licensed cevidoplenib, an oral SYK inhibitor, from Oscotec in June 2026 for USD 25 million upfront and up to USD 140 million in regulatory milestones. Different mechanisms may support combination approaches, including targeted therapy used with a thrombopoietin receptor agonist.

Orphan-Disease Incentives and Specialty-Hematology Investment

Orphan-drug frameworks influence investment decisions in the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market. Rilzabrutinib received FDA Fast Track and Orphan Drug Designation before approval, and the designation provides 7 years of U.S. market exclusivity after launch. Takeda’s mezagitamab received orphan drug designation in Japan for chronic ITP in July 2025. Gilead and Lakefront completed the acquisition of Ouro Medicines in June 2026 for USD 1.7 billion, adding gamgertamig to their inflammation portfolio. The transaction included up to USD 500 million in contingent milestone payments. These incentives and transactions support continued research in a specialized treatment area.

High Annual Cost of Novel Therapies

Treatment cost is a central access constraint for the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market. Annual all-cause costs for treated chronic ITP patients averaged USD 34,293, compared with USD 8,895 for untreated patients. Direct ITP therapy costs averaged USD 8,838 per patient each year. The cited Italian analysis reported annual costs of EUR 11,397 (USD 12,328) for patients receiving high-dose or high-intensity corticosteroid regimens. Payers often require the use of corticosteroids, intravenous immunoglobulin, or generic immunosuppressants before authorizing newer options. Newly launched therapies also face scrutiny because long-term real-world evidence is limited.

Variable Reimbursement and Prior Authorization

Reimbursement differences can delay access to novel ITP therapies. Prior authorization for thrombopoietin receptor agonists and targeted agents may delay dispensing by weeks or months in U.S. community practices. Treatment placement remains uncertain for BTK inhibitors, FcRn antagonists, and anti-CD38 antibodies. This uncertainty encourages payers to favor established and lower-cost options. The result can restrict new therapies to refractory patients rather than earlier treatment lines. Safety monitoring and concerns around thrombosis further reinforce cautious sequencing decisions, particularly for older patients with comorbidities.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Duration and Phase: Chronic ITP Anchors Revenue While Refractory Patients Drive Innovation

Chronic ITP held 47.60% of the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market share in 2025. This position reflects the need for long-term management after patients move beyond the newly diagnosed disease. Newly diagnosed ITP is often treated with short courses of corticosteroids and intravenous immunoglobulin. Persistent disease remains an important transition period between 3 and 12 months. Refractory or relapsed ITP is forecast to grow at an 8.10% CAGR through 2031. This group requires more intensive use of thrombopoietin receptor agonists, SYK inhibitors, and emerging biologics.

Rilzabrutinib was approved for adults with persistent or chronic ITP who had not responded sufficiently to previous treatment. The approval added an oral targeted choice for patients who previously had limited alternatives beyond splenectomy or off-label rituximab. Persistent ITP is gaining attention as a possible earlier treatment window. A 2025 Chinese real-world study reported an 89% initial response rate with first-line romiplostim plus low-dose dexamethasone in patients aged at least 60 years. The study reported stronger 6-month sustained remission than corticosteroid monotherapy. This evidence challenges the practice of delaying thrombopoietin receptor agonists until chronic disease.

By Treatment Type: TPO-RAs Dominate but Face Structural Disruption from Novel Classes

Thrombopoietin receptor agonists held 38.90% of the treatment type share in 2025. Romiplostim, eltrombopag, and avatrombopag support this leading position. Corticosteroids retain a major role in newly diagnosed and acute presentations. Intravenous immunoglobulin and anti-D immunoglobulin remain relevant in rescue care and surgical preparation. Immunosuppressants and splenectomy have declined as targeted oral options have entered broader practice. The Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market size for targeted classes is growing as treatment choices diversify.

Monoclonal antibodies and targeted biologics are forecast to grow at an 11.40% CAGR through 2031. This class includes the BTK inhibitor rilzabrutinib and investigational intravenous efgartigimod. The ADVANCE NEXT Phase 3 study of intravenous efgartigimod began in October 2024 and has an expected completion in 2028. Gilead’s acquired gamgertamig is expected to move toward registrational studies from 2027. Fostamatinib and pipeline cevidoplenib offer a SYK-focused approach that differs from stimulating platelet production. This treatment diversity supports use in patients who do not respond to a single pathway.

By Route of Administration: Oral Agents Reshape the Delivery Landscape

Oral therapies accounted for 51.80% of revenue in 2025. Oral thrombopoietin receptor agonists, especially eltrombopag, established much of this share. Rilzabrutinib is also an oral therapy administered at 400 mg twice daily. Oral treatment can reduce the need for clinic visits for long-term platelet management. This delivery option can lower healthcare resource use and ease the logistical burden for patients. Intravenous treatment remains important for intravenous immunoglobulin and for patients needing rescue care.

Subcutaneous therapies are forecast to grow at a 10.20% CAGR through 2031. Romiplostim has a subcutaneous delivery format that can support home injection. The development of subcutaneous biologics also aims to reduce infusion burden. The Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market share of infusion-dependent maintenance care may narrow as oral and home-compatible options expand. Long-term data cited for responding patients showed platelet counts above 50 × 10⁹/L during more than half of monthly visits over a median of 1.3 years. These options can shift maintenance therapy away from infusion centers without removing the role of acute intravenous treatment.

By Patient Age Group: Geriatric ITP Demands Age-Adapted Protocols

Adults held 72.40% of the patient age group revenue in 2025. This reflects the large long-term treatment population among working-age and middle-aged adults. Pediatric access expanded after the FDA approved avatrombopag for patients aged 1 year and older in July 2025. The approval included Doptelet Sprinkle oral granules for children aged 1 to under 6 years. In AVA-PED-301, 81.5% of pediatric patients achieved an alternative platelet response, compared with 0% for placebo.

The geriatric group is forecast to grow at a 7.60% CAGR through 2031. ITP incidence reached 9 per 100,000 person-years in French men aged over 75 and 23.9 per 100,000 in British men aged over 80. Comorbidities, polypharmacy, thrombosis risk, and infection risk complicate treatment decisions in older adults. These considerations can limit the practical use of corticosteroids, rituximab, and splenectomy. A cited real-world analysis reported sustained response in 72% of treated elderly patients using thrombopoietin receptor agonists, with a mean maintenance platelet count of 75 × 10⁹/L. The results reinforce the role of tolerated targeted therapies in older patients. ^{[2]Source: Frontiers in Immunology, “Age-Related and Disease-Specific Changes in B-Cell Profiles in Older Adults With Immune Thrombocytopenia,” Frontiers in Immunology, frontiersin.org.}

By Distribution Channel: Hospital Pharmacies Lead as Specialty Networks Scale

Hospital pharmacies held 52.30% of the distribution channel revenue in 2025. Their position reflects physician-administered intravenous immunoglobulin, subcutaneous romiplostim, and intravenous biologics. Hospital dispensing remains linked to therapies that need clinical administration or monitoring. Retail pharmacies mainly supply adjunctive and generic medicines rather than specialized ITP therapies. Specialty pharmacies are forecast to grow at an 8.8% CAGR through 2031. This channel supports the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market by managing complex access and adherence needs.

Sanofi selected Biologics by McKesson as a limited specialty pharmacy provider for Wayrilz in September 2025. The arrangement includes patient financial assistance and adherence support services. Limited specialty networks can give manufacturers more visibility into prescribing patterns and patient outcomes. They also give payers a concentrated point for formulary negotiations. Clinical coordinators and nurses in these networks can reduce administrative delays during the move from hospital-based care to oral treatment. The model may improve support while also making patient access sensitive to network restrictions.

Geography Analysis

North America held 43.10% of the Idiopathic Thrombocytopenic Purpura (ITP) therapeutics market share in 2025. The United States benefits from academic hematology centers, specialty pricing, insurance coverage, and quick uptake after FDA approvals. Wayrilz launched in the United States through limited specialty pharmacies in September 2025^{[3]Source: Biologics by McKesson, “WAYRILZ Available at Biologics by McKesson,” Biologics by McKesson, biologics.mckesson.com.}. Canada is expanding public review activity for orphan hematology medicines. Mexico is improving diagnostic capture through urban tertiary hospital networks. Amgen, Novartis, Rigel, and Sanofi compete across overlapping later-line treatment settings in the region.

Europe held the second-largest regional position in 2025. Germany, the United Kingdom, France, Italy, and Spain each have different reimbursement systems. This creates uneven access to premium therapies across the region. The United Kingdom’s health technology assessment process and Germany’s AMNOG framework can limit use when direct comparative evidence is limited. Patient advocacy groups and investigator-led trial networks support treatment awareness and study participation. Orphan-drug designations and European regulatory reviews provide a pathway for new therapies, including rilzabrutinib.

Asia-Pacific is forecast to grow at a 9.30% CAGR through 2031. Japan approved avatrombopag for persistent and chronic ITP in August 2025, and Sanofi filed rilzabrutinib for Japanese marketing approval in October 2025. China’s 2025 guideline includes SYK and BTK inhibitors as subsequent treatment options. This supports domestic participants such as Jiangsu Hengrui’s hetrombopag and 3SBio’s recombinant TPO, while lowering barriers for international entrants. South Korea, India, and Australia add growth through wider hematology access and orphan-drug reviews. Middle East and Africa and South America remain smaller, although GCC tertiary centers and Brazilian patient registries support future therapy expansion.